DRUG
Price
$41.37
Change
-$1.58 (-3.68%)
Updated
Nov 15, 03:16 PM (EDT)
OTLC
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Nov 14 closing price
3 days until earnings call
Ad is loading...

DRUG vs OTLC

Header iconDRUG vs OTLC Comparison
Open Charts DRUG vs OTLCBanner chart's image
Bright Minds Biosciences
Price$41.37
Change-$1.58 (-3.68%)
Volume$686
CapitalizationN/A
Oncotelic Therapeutics
Price$0.03
Change-$0.00 (-0.00%)
Volume$37.24K
CapitalizationN/A
DRUG vs OTLC Comparison Chart
Loading...
View a ticker or compare two or three
VS
DRUG vs. OTLC commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DRUG is a Sell and OTLC is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (DRUG: $42.95 vs. OTLC: $0.03)
Brand notoriety: DRUG and OTLC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DRUG: 5% vs. OTLC: 10%
Market capitalization -- DRUG: $300.09M vs. OTLC: $11.27M
DRUG [@Biotechnology] is valued at $300.09M. OTLC’s [@Biotechnology] market capitalization is $11.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DRUG’s FA Score shows that 0 FA rating(s) are green whileOTLC’s FA Score has 1 green FA rating(s).

  • DRUG’s FA Score: 0 green, 5 red.
  • OTLC’s FA Score: 1 green, 4 red.
According to our system of comparison, OTLC is a better buy in the long-term than DRUG.

Price Growth

DRUG (@Biotechnology) experienced а -11.48% price change this week, while OTLC (@Biotechnology) price change was -4.31% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.92%. For the same industry, the average monthly price growth was -3.16%, and the average quarterly price growth was +1.65%.

Reported Earning Dates

DRUG is expected to report earnings on Aug 28, 2023.

OTLC is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-5.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

FUNDAMENTALS
Fundamentals
DRUG($300M) has a higher market cap than OTLC($11.3M). DRUG YTD gains are higher at: 2903.497 vs. OTLC (-27.451).
DRUGOTLCDRUG / OTLC
Capitalization300M11.3M2,655%
EBITDAN/AN/A-
Gain YTD2903.497-27.451-10,577%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
OTLC: Fundamental Ratings
OTLC
OUTLOOK RATING
1..100
83
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
61
P/E GROWTH RATING
1..100
95
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
RSI
ODDS (%)
Stochastic
ODDS (%)
Momentum
ODDS (%)
MACD
ODDS (%)
TrendWeek
ODDS (%)
TrendMonth
ODDS (%)
Advances
ODDS (%)
Declines
ODDS (%)
BollingerBands
ODDS (%)
Aroon
ODDS (%)
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

DRUG and

Correlation & Price change

A.I.dvisor indicates that over the last year, DRUG has been loosely correlated with PHMMF. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if DRUG jumps, then PHMMF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DRUG
1D Price
Change %
DRUG100%
+1.85%
PHMMF - DRUG
44%
Loosely correlated
N/A
LBPH - DRUG
35%
Loosely correlated
-0.07%
ATYR - DRUG
32%
Poorly correlated
-9.37%
SEER - DRUG
29%
Poorly correlated
+4.76%
PHGUF - DRUG
28%
Poorly correlated
N/A
More

OTLC and

Correlation & Price change

A.I.dvisor tells us that OTLC and THAR have been poorly correlated (+25% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OTLC and THAR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OTLC
1D Price
Change %
OTLC100%
+5.51%
THAR - OTLC
25%
Poorly correlated
+2.29%
DRUG - OTLC
20%
Poorly correlated
+1.85%
CANF - OTLC
20%
Poorly correlated
-3.86%
MMIRF - OTLC
15%
Poorly correlated
N/A
IUGNF - OTLC
6%
Poorly correlated
+4.92%
More